Jazz Pharmaceuticals (FRA:J7Z) Total Stockholders Equity : €3,401 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Total Stockholders Equity?

Jazz Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €3,401 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Jazz Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €53.96. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Jazz Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 was 1.57.

Jazz Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Jazz Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Total Stockholders Equity Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

2,799.88

3,008.31

3,509.19

2,912.93

3,426.83

Jazz Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															3,114.93	3,254.20	3,269.54	3,426.83	3,400.74

Jazz Pharmaceuticals (FRA:J7Z) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Jazz Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3400.744	-	0)	/	63.028
	=	53.96

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Jazz Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(573.833	+	4748.367)	/	3400.744
	=	1.57

Jazz Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (FRA:J7Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

JAZZ:USA JAZZ:Mexico

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines